{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000033","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.600192+00:00","generated_at":"2026-06-15T02:54:57.748596+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired","bullets":["Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).","Cash and marketable securities $392.0M at March 31, 2023, down from $467.9M at Dec 31, 2022.","Acquired exclusive global rights (ex-China) to TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.","Appointed Nick Kozauer (former FDA Division Director) as SVP of Clinical Development and Regulatory Strategy.","Anticipates H2 2023: Phase 2/3 for BHV-7000 in epilepsy/bipolar; IND submissions for BHV-7010, -2100, -1300."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000033","json":"https://secwatch.observer/filing/0001935979-23-000033.json","markdown":"https://secwatch.observer/filing/0001935979-23-000033.md","text":"https://secwatch.observer/filing/0001935979-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/0001935979-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/bhvn-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:54:57.748596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52801167853feb2c75a9e7b4d6b0cfee8f51969d","claim":"Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 12, 2023, Biohaven Ltd. (the “ Registrant ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000033/0001935979-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}